Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study seeks to identify whether the addition of liposomal bupivacaine to regular
bupivacaine and saline administered via surgical transversus abdominis plane (TAP) block will
reduce the cumulative opioid dose in the first 48 hours after cesarean. 60 women scheduled
for cesarean at Unity-Point Health Meriter Hospital in Madison, Wisconsin will be enrolled
and can be expect to be on study for up to 6 weeks post-partum.
Phase:
Phase 4
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
UnityPoint Health-Meriter UnityPoint Health-Meriter Foundation